Search Clinical Trials
Sponsor Condition of Interest |
---|
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
Theravance Biopharma
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma
pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib
(TD-0903) with supplemental oxygenation. expand
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation. Type: Interventional Start Date: Oct 2021 |
The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
National Bureau of Economic Research, Inc.
Covid19
Facebook ads with physician-delivered videos were shown before the Thanksgiving and
Christmas holidays and focused on staying safe during the COVID pandemic by limiting
travel and mask-wearing. expand
Facebook ads with physician-delivered videos were shown before the Thanksgiving and Christmas holidays and focused on staying safe during the COVID pandemic by limiting travel and mask-wearing. Type: Interventional Start Date: Nov 2020 |
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Evidation Health
Covid19
SARS-CoV Infection
Prospective, observational, exploratory study exploring the relationship between
passively-collected data from wearable activity devices and SARS-CoV-2 infection expand
Prospective, observational, exploratory study exploring the relationship between passively-collected data from wearable activity devices and SARS-CoV-2 infection Type: Observational Start Date: Nov 2020 |
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
The primary objective of this study is to evaluate the safety and tolerability of V590
versus placebo and to assess the immunogenicity of V590 on Day 28. The primary hypothesis
is that at least one well-tolerated dose of V590 increases the geometric mean titers
(GMTs) of anti-severe acute respiratory... expand
The primary objective of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28. The primary hypothesis is that at least one well-tolerated dose of V590 increases the geometric mean titers (GMTs) of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike serum neutralizing antibody, as measured by plaque reduction neutralization test (PRNT), compared to placebo. Type: Interventional Start Date: Oct 2020 |
Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's...
National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
Functional Movement Disorders
COVID-19
The purpose of this study is to investigate the clinical correlates of the effects of the
COVID-19 pandemic on patients with Functional movement disorder (FMD) and Parkinson s
Disease (PD).
Primary objectives:
To evaluate the change in neurological symptoms domain of the survey between pre and
post-COVID... expand
The purpose of this study is to investigate the clinical correlates of the effects of the COVID-19 pandemic on patients with Functional movement disorder (FMD) and Parkinson s Disease (PD). Primary objectives: To evaluate the change in neurological symptoms domain of the survey between pre and post-COVID 19 in FMD and PD patients. Secondary objectives: - To evaluate the change in total score of the survey between pre and post COVID 19 in FMD and PD patients - To evaluate the change in other symptom domains of the survey between pre and post COVID 19 in FMD and PD patients. Domains include: Mood/Energy, sleep, symptoms of abnormal movements related or unrelated to primary disease, physical health and exercise related change Exploratory objectives: - To evaluate whether there is a modifying effect of disease group in the changes in total score or symptom domains - To evaluate whether there is a relationship between disease severity and changes in total score or symptom domains - To evaluate whether there is a correlation between changes across symptom domains - To evaluate whether there is a correlation in raw score across symptom domains within each period Research Methods: Data will be solely collected through the use of online instruments via CiSTAR as a designed questionnaire. Questionnaire items A questionnaire aimed at determining the effects of the COVID 19 pandemic and subsequent isolation on functional state of patients with FMD and PD. The questionnaire items include: Items investigating Mood/Energy before and after COVID 19 out break Items investigating Sleep habits before and after COVID 19 out break Items investigating Neurological symptoms before and after COVID 19 out break Items investigating daily functioning before and after COVID 19 out break Items investigating Exercise habits before and after COVID 19 out break No questionnaire items will be actionable , which are items that would identify an imminent risk for participant safety requiring urgent and immediate medical or psychiatric Type: Observational Start Date: Oct 2020 |
Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
Viela Bio
Acute Lung Injury
The study aims to assess the potential benefit and evaluate the safety and tolerability
of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented
infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary
involvement. Subjects will be administered... expand
The study aims to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Subjects will be administered a single dose of VIB7734 injected under the skin, assessed for efficacy for 28 days and followed for an additional 42 days. Type: Interventional Start Date: Aug 2020 |
A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants...
Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
The primary objective of this early Phase 1/2 study is to identify the V591 dose that
achieves the target immune response in humans based on preclinical or early clinical
data. expand
The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data. Type: Interventional Start Date: Aug 2020 |
Atovaquone for Treatment of COVID-19
University of Texas Southwestern Medical Center
COVID-19
The purpose of the current study is to accelerate the use of a clinically available
therapeutic already FDA-approved for other indications in the setting of pandemic
COVID-19 addressing a serious and emergent unmet medical need.
This is a randomized, double-blind study of atovaquone therapy in adult... expand
The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and emergent unmet medical need. This is a randomized, double-blind study of atovaquone therapy in adult participants hospitalized with COVID-19. Approximately 60 participants who meet all eligibility criteria may be randomized in a 2:1 atovaquone/placebo ratio into one of the following treatment groups: Treatment Group 1: continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days Treatment Group 2: continued standard of care therapy together with matching placebo Type: Interventional Start Date: Jul 2020 |
Vitamin D Testing and Treatment for COVID 19
Arizona State University
Covid 19
Vitamin D Deficiency
This study will measure vitamin D levels in adults with COVID 19. Participants with low
levels of vitamin D will be entered into an open label trial of supplementation with
vitamin D. expand
This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D. Type: Interventional Start Date: May 2020 |
Pulmozyme to Improve COVID-19 ARDS Outcomes
Boston Children's Hospital
COVID
This is a randomized double-blind placebo-controlled Phase II trial of recombinant human
deoxyribonuclease I (rhDNase I) - Pulmozyme - in mechanically ventilated patients with
COVID-19 pneumonia.
Patients admitted to the ICU with severe COVID-19 pneumonia who require mechanical
ventilation will... expand
This is a randomized double-blind placebo-controlled Phase II trial of recombinant human deoxyribonuclease I (rhDNase I) - Pulmozyme - in mechanically ventilated patients with COVID-19 pneumonia. Patients admitted to the ICU with severe COVID-19 pneumonia who require mechanical ventilation will be invited to participate in this study. Potential subjects will be identified from medical record review or from direct contact with physicians. Investigators will check medical history and confirm eligibility. Informed consent will be obtained from either the patient or designated healthcare proxy. 60 subjects will be enrolled. After obtaining informed consent, patients will be randomized 2:1 to Pulmozyme 2.5 mg BID for up to 28 days or until they are no longer receiving mechanical ventilation, whichever is sooner plus standard of care vs. placebo normal saline 2.5 ml plus standard of care. Type: Interventional Start Date: Jul 2020 |
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
TriHealth Inc.
Coronavirus
COVID-19
Convalescent Plasma
Purpose of Study
• The purpose of this study to evaluate, the effectiveness of convalescent plasma in
combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond
supportive care, there are no proven treatment options for COVID-19. expand
Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19. Type: Interventional Start Date: May 2020 |
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
Sanford Health
COVID-19
SARS-CoV 2
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct
cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of
COVID-19 infection. expand
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection. Type: Interventional Start Date: May 2020 |
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory...
Kinevant Sciences GmbH
COVID-19
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind,
placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with
lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19. expand
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19. Type: Interventional Start Date: Apr 2020 |
Convalescent Plasma vs. Standard Plasma for COVID-19
Stony Brook University
COVID
The purpose of this study is to find out if transfusion of blood plasma containing
antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who
recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized
patients.
Antibodies are blood proteins produced... expand
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse. Type: Interventional Start Date: Apr 2020 |
Paradoxical Response to Chest Wall Loading in Mechanically Ventilated Patients
HealthPartners Institute
ARDS
COVID-19
Mechanical Ventilation Pressure High
Ventilator-Induced Lung Injury
The purposes of our study are to: 1) determine the incidence of paradoxical response to
chest wall loading in mechanically ventilated patients; 2) identify sub-populations in
which it is most likely to occur (e.g., severe ARDS); and 3) standard the bedside
procedure for demonstrating this physiology. expand
The purposes of our study are to: 1) determine the incidence of paradoxical response to chest wall loading in mechanically ventilated patients; 2) identify sub-populations in which it is most likely to occur (e.g., severe ARDS); and 3) standard the bedside procedure for demonstrating this physiology. Type: Interventional Start Date: Dec 2021 |
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
University of Washington
SARS-CoV-2 Infection
COVID-19
Coronavirus Infection
SARS (Severe Acute Respiratory Syndrome)
Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are
underway under separate protocol(s) for close contacts (i.e., household contacts,
[e.g.,3502]) of infectious (index) individuals... expand
Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are underway under separate protocol(s) for close contacts (i.e., household contacts, [e.g.,3502]) of infectious (index) individuals (3502-01). Characterizing the index individuals within households will ascertain the risk of exposure for the contact participant. These data will be used to strengthen the precision of efficacy estimates. This ancillary observational study will assess the cofactors for infectiousness among index individuals whose close contacts are enrolled in COVID-19 prevention clinical trials. Additionally, this study will assess post-acute sequelae of SARS-CoV-2 infection in index individuals that are more than two weeks past their initial diagnosis. Type: Observational Start Date: Dec 2020 |
Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen
Columbia University
Covid19
This study aims to assess how an at-home COVID-19 frequent testing regimen using the
CoV-SCAN test kit and a paired phone application to help interpret the test result
compares to once-a-week or three-times-a-week polymerase chain reaction (PCR) (molecular)
testing to identify a SARS-CoV-2 infection.
Employees... expand
This study aims to assess how an at-home COVID-19 frequent testing regimen using the CoV-SCAN test kit and a paired phone application to help interpret the test result compares to once-a-week or three-times-a-week polymerase chain reaction (PCR) (molecular) testing to identify a SARS-CoV-2 infection. Employees and cast members at Media and Entertainment Company and its affiliates will be recruited to test whether frequent use of CoV-SCAN will perform as well or better than weekly molecular testing and at least as well as three-times-a-week molecular testing. Type: Observational Start Date: Feb 2021 |
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019...
Gilead Sciences
COVID-19
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in
reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or
all-cause death in non-hospitalized participants with early stage COVID-19 and to
evaluate the safety of RDV administered... expand
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting. Type: Interventional Start Date: Sep 2020 |
Convalescent Plasma in Pediatric COVID-19
Emory University
COVID
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been
adequately studied in children to date. The study will determine safety of convalescent
plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease. expand
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease. Type: Interventional Start Date: Jul 2020 |
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
Duke University
COVID-19
SARS-CoV 2
The primary objective is to use "network targeted sampling design" to detect active
and/or undiagnosed cases of COVID-19 in the community and determine the spread or
distribution of 1) active infection, and 2) past exposure. The hypothesis is that there
are many undiagnosed and/or asymptomatic people... expand
The primary objective is to use "network targeted sampling design" to detect active and/or undiagnosed cases of COVID-19 in the community and determine the spread or distribution of 1) active infection, and 2) past exposure. The hypothesis is that there are many undiagnosed and/or asymptomatic people in the community who may be unknowingly spreading the virus or have been exposed and have antibodies. We propose to implement respondent-driven sampling (RDS) which leverages effort on the part of seed or index cases to recruit contacts for participation. Type: Observational Start Date: Dec 2020 |
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Eli Lilly and Company
COVID-19
The purpose of this study is to test the safety and tolerability of LY3819253 when it is
given by injection into a vein to participants hospitalized with COVID-19. Blood tests
will be done to check how much LY3819253 is in the bloodstream and how long the body
takes to eliminate it. Participation... expand
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home. Type: Interventional Start Date: May 2020 |
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Matthew Dallos
Solid Tumor
Sars-CoV2
Hematological Malignancy
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19).
The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with
BMS-986253 can help improve the health condition of participants infected with COVID-19.
This is the first in-human study of... expand
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study. Type: Interventional Start Date: Apr 2020 |
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
Iterum Therapeutics, International Limited
Respiratory Tract Infection Viral
This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and
microbiologic response of patients with a respiratory tract infection (RTI) due to
coronavirus treated with a combination of azithromycin and hydroxychloroquine.
Approximately 200 patients with symptoms of an RTI... expand
This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and microbiologic response of patients with a respiratory tract infection (RTI) due to coronavirus treated with a combination of azithromycin and hydroxychloroquine. Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy. Type: Interventional Start Date: Feb 2021 |
The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry
Boston Children's Hospital
Airway Management
COVID19
The COVID-19 pandemic has disrupted anesthesia care all over the world. There remains
very little data on current practice patterns and patient outcomes, particularly in
anesthetized children. This is a prospective observational, multi-center study to
investigate airway management related outcomes... expand
The COVID-19 pandemic has disrupted anesthesia care all over the world. There remains very little data on current practice patterns and patient outcomes, particularly in anesthetized children. This is a prospective observational, multi-center study to investigate airway management related outcomes in children undergoing anesthesia during this pandemic. The investigators will compare the incidence of complications (particularly hypoxemia) in patients with COVID-19 to those who are COVID-19 negative during airway management. PAWS COVID-19 Registry https://is.gd/PEDICOVID19 Registration link https://is.gd/researchrequest Type: Observational [Patient Registry] Start Date: Apr 2020 |
Risks of COVID19 in the Pregnant Population
Mayo Clinic
COVID19
It is unclear how COVID19 can be passed from mother to infant. The study investigators
aim to collect maternal and neonatal samples from COVID19-infected pregnant women and
compare them to pregnant women who have clinical indications for COVID 19 testing at the
time of hospital admission but end up... expand
It is unclear how COVID19 can be passed from mother to infant. The study investigators aim to collect maternal and neonatal samples from COVID19-infected pregnant women and compare them to pregnant women who have clinical indications for COVID 19 testing at the time of hospital admission but end up being COVID19 negative. Pregnant women who are either COVID19 positive or COVID19 negative with respiratory symptoms will be enrolled and followed during this study. Type: Observational Start Date: May 2020 |
- Previous
- Next